Associate Professor
Department of Pathology & Immunology
Baylor College of Medicine
Houston, TX, US

Professional Statement

My laboratory is actively researching Clostridium difficile pathogenesis and we were the first to identify toxin B as the major virulence factor in human intestine. We also identified a novel innate host defense mechanism against microbial toxin and pioneered new therapeutic concepts which we termed “allosteric therapeutics”.

My research has also played a central role in discovering novel glial cell functions in the gut.

Selected Publications


Allosteric therapy of the Clostridium difficile toxins - #R01 NIAID AI10094001
Grant funding from NIH R01
The goal of this study is to develop novel allosteric inhibitors for the C. difficile toxins using inositolphosphate analogs and S-nitrosothiol biology.
Metabolome-Based Biomarkers and Neutraceuticals in Clostridium Difficile Infection. - #R21DK096323-01
Grant funding from NIH R21
The goal of this study is to develop validate metabolomics biomarkers of disease susceptibility to Clostridium difficile.


Expert Omics review
NASA Human Research Roadmap for 2035 Mission to Mars.
Editorial Board
American Journal of Physiology (Gastroenterology & Hepatology).